Serevent Powder, Metered
Product Images NDC 0173-0521

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Serevent (NDC 0173-0521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Salmeterol Chemical Structure (Sereventdiskus Spl Graphic 01)

Salmeterol Chemical Structure (Sereventdiskus Spl Graphic 01)
FDA Label Image

Figure 1 First Treatment Day (Sereventdiskus Spl Graphic 02)

Figure 1 First Treatment Day (Sereventdiskus Spl Graphic 02)
FDA Label Image

Figure 1 Week 12 (Sereventdiskus Spl Graphic 03)

Figure 1 Week 12 (Sereventdiskus Spl Graphic 03)
FDA Label Image

Figure 2. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (Sereventdiskus Spl Graphic 04)

Figure 2. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (Sereventdiskus Spl Graphic 04)
FDA Label Image

Figure 3. Mean Percent Change From Baseline In Postdose Fev1 Integrated Data From 2 Trials Of Subjects With Chronic Bronchitis And Airflow Limitation (Sereventdiskus Spl Graphic 05)

Figure 3. Mean Percent Change From Baseline In Postdose Fev1 Integrated Data From 2 Trials Of Subjects With Chronic Bronchitis And Airflow Limitation (Sereventdiskus Spl Graphic 05)
Description not available. The given text contains some characters which cannot be recognized.*
FDA Label Image

Figure 4. Serial 12-hour Fev1 On The First Day And At Week 12 Of Treatment (Sereventdiskus Spl Graphic 06)

Figure 4. Serial 12-hour Fev1 On The First Day And At Week 12 Of Treatment (Sereventdiskus Spl Graphic 06)
FDA Label Image

Figure A (Sereventdiskus Spl Graphic 07)

Figure A (Sereventdiskus Spl Graphic 07)
FDA Label Image

Figure B (Sereventdiskus Spl Graphic 08)

Figure B (Sereventdiskus Spl Graphic 08)
FDA Label Image

Figure C (Sereventdiskus Spl Graphic 09)

Figure C (Sereventdiskus Spl Graphic 09)
FDA Label Image

Figure D (Sereventdiskus Spl Graphic 10)

Figure D (Sereventdiskus Spl Graphic 10)
FDA Label Image

Figure E (Sereventdiskus Spl Graphic 11)

Figure E (Sereventdiskus Spl Graphic 11)
FDA Label Image

Figure F (Sereventdiskus Spl Graphic 12)

Figure F (Sereventdiskus Spl Graphic 12)
FDA Label Image

Figure G (Sereventdiskus Spl Graphic 13)

Figure G (Sereventdiskus Spl Graphic 13)
FDA Label Image

Serevent Diskus 50 Mcg 60 Dose Carton (Sereventdiskus Spl Graphic 14)

Serevent Diskus 50 Mcg 60 Dose Carton (Sereventdiskus Spl Graphic 14)
Serevent Diskus is an oral inhalation medication that contains salmeterol xinafoate. Each blister contains 50 mcg of salmeterol base with lactose monohydrate. The NDC code for this medication is 0173-0521-00. Prescribing information for the DISKUS Inhalation Device and dosing information can be found on the package.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.